Vipergen in brief
- Vipergen is a world leading provider of small molecule drug discovery services based on DNA-encoded library (DEL) technologies
- Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies
- Vipergen introduces the YoctoReactor® (yR) and Binder Trap Enrichment® (BTE) – 2nd generation DEL technologies
- Vipergen introduces the cellular Binder Trap Enrichment® (cBTE) – 3rd generation DEL screening technology (New – commercial release 2020Q4)
- The yR, BTE and cBTE technology platforms are exclusively owned by Vipergen and secured by strong patent positions
- Vipergen is offering different business models, including simple Fee-For-Service.
- In 2015-22 >75 deals signed, including with top-5 pharma in both USA, EU and Japan
- The company is privately owned by Gunnar Kjems and Dr. Nils Hansen
- Board members: Gunnar Kjems (chair) and Dr. Nils Hansen
- Founded by CEO, Dr. Nils Hansen
- Founded in 2005
- Incorporated in Copenhagen, Denmark